XBiotech Inc.
XBiotech Inc. is tracked here for clinical trial milestones, SEC filings and earnings dates. Focus area: Pharmaceutical Preparations.
The next scheduled catalyst is Natrunix in Combination With Methotrexate for Rheumatoid Arthritis Treatment on January 15, 2027. There are 2 upcoming events on record.
Cash runway is approximately 36.6 months based on the most recent reported cash position and quarterly operating burn as of 2026-06-30.
Across 5 concluded trials, 100% reached completion rather than being terminated or withdrawn.
| Date | Event | Type | Phase |
|---|---|---|---|
| January 15, 2027 | Natrunix in Combination With Methotrexate for Rheumatoid Arthritis Treatment | Trial Milestone | Phase 2 |
| September 15, 2028 | Vilamakitug in Spondyloarthritis Placebo-controlled Investigation for Efficacy | Trial Milestone | Phase 2 |
Track XBIT alongside other companies. Add it to a watchlist and see every catalyst on one calendar.
Open XBIT in the tracker| Date | Event | Type | Phase |
|---|---|---|---|
| December 9, 2025 | 8-K filed: Leadership change | Corporate | — |
| October 15, 2025 | 8-K/A filed: Leadership change | Corporate | — |
| October 3, 2025 | 8-K filed: Material agreement, Leadership change | Corporate | — |
| June 24, 2025 | 8-K filed: Leadership change | Corporate | — |
| October 31, 2024 | Natrunix or Placebo in Combination With Methotrexate in Rheumatoid Arthritis | Trial Milestone | Phase 2 |
| October 26, 2023 | XB2001 in Combination With ONIVYDE + 5-FU/LV (+Folinic Acid) in Advanced Pancreatic Cancer | Trial Milestone | Phase 1/Phase 2 |
| October 24, 2023 | Hutrukin to Analyze Safety and PK in Healthy Volunteers | Trial Milestone | Phase 1 |
| August 8, 2022 | Safety and Pharmacokinetics (PK) Study of Natrunix in Healthy Volunteers | Trial Milestone | Phase 1 |
| December 15, 2016 | Safety & Efficacy of True Human Antibody, 514G3, in Staphylococcus Aureus Bacteremia Hospitalized Subjects. | Trial Milestone | Phase 1/Phase 2 |
Trial milestones come from the ClinicalTrials.gov v2 API, filings from SEC EDGAR, and financial figures from SEC XBRL company facts. Dates marked est. are projected rather than company-confirmed. This is an information tool, not investment advice — verify anything you act on against the linked primary source.
Last updated 2026-10-14.